TOPLINE: In a first in-human study, KITE-363, an anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, showed high rates of response in patients with highly refractory large B-cell lymphoma (LBCL). The bicistronic, autologous CAR T-cell therapy, designed to prevent CD19 escape through the upfront targeting of CD19 and CD20…
Leave a Comment Leave a Comment
